Healthcare Professionals

A Foundation of Clinical Evidence

The Corvia Atrial Shunt is the most clinically studied atrial shunt for the reduction of Left Atrial Pressure (LAP) in HFpEF/HFmrEF patients. Over 750 patients have been studied to date and multiple studies are ongoing.


Corvia Atrial Shunts
implanted globally


Implanted patient-years of follow-up1


Years post-implant for the longest ongoing Corvia Atrial Shunt patients1


Peer-reviewed publications
on the Corvia Atrial Shunt performance & mechanism of action

REDUCE LAP-HF Clinical Program

Corvia Medical, in collaboration with its clinical investigators and advisors, is committed to generating and sharing unbiased evidence to support atrial shunting therapy for heart failure. Through multiple REDUCE LAP-HF studies around the world, clinical results have consistently established the safety of the Corvia Atrial Shunt System and have demonstrated encouraging efficacy in heart failure patients with an EF≥40% and elevated left atrial pressure.

REDUCE LAP-HF II Trial Results

Results from this landmark study are now available! REDUCE LAP-HF II is the largest randomized clinical trial of a device-based therapy in HFpEF. 

Clinical Evidence Summary: Pilot Study, REDUCE LAP-HF, REDUCE LAP-HF I


Immediate and significant PCWP reduction of 3-5mmHG with clinical improvement sustained over 12 months.2


The Corvia Atrial Shunt demonstrated consistent, durable results in nearly 100 patients across 3 studies.


Freedom from stroke (CVA) @ 3 years3


of RV failure
out to 5 years3


Patency @ 1 year4-6


Cases of implant removal, closure, or thrombosis through 8 years7

  1. Unpublished data on file at Corvia Medical. Data as of January 14, 2022.
  2. Feldman T, Mauri L, Kahwash, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I): A Phase 2, Randomized, Sham-Controlled Trial. Circ. 2018;137(4):364-375.
  3. Unpublished data compiled from Corvia Pilot Study (n=11), REDUCE LAP-HF (n=64), and REDUCE LAP-HF I (n=22 randomized to treatment). Data on file at Corvia Medical.
  4. Kaye DM, Hasenfuß G, Neuzil P, et al. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure with Preserved Ejection Fraction. Circ Heart Fail. 2016 Dec; 9(12).
  5. Unpublished data from Corvia Pilot Study (n=11). Data on file at Corvia Medical.
  6. Shah S J, Feldman T, Ricciardi MJ, et al. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018 Oct 1;3(10):968-977.
  7. Unpublished data compiled from all Corvia implants as of September 1, 2021. Data on file at Corvia Medical.